Author Correction: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Autorzy:
Momont C; Vir Biotechnology, San Francisco, CA, USA. Dang HV; Vir Biotechnology, San Francisco, CA, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Hauser K; Vir Biotechnology, San Francisco, CA, USA. Wang C; Vir Biotechnology, St. Louis, MO, USA. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Minola A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Branch K; Vir Biotechnology, San Francisco, CA, USA. Donermeyer D; Vir Biotechnology, St. Louis, MO, USA. Vyas S; Vir Biotechnology, San Francisco, CA, USA. Chen A; Vir Biotechnology, San Francisco, CA, USA. Ferri E; Vir Biotechnology, San Francisco, CA, USA. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Powell AE; Vir Biotechnology, San Francisco, CA, USA. Spreafico R; Vir Biotechnology, San Francisco, CA, USA. Yim SS; Vir Biotechnology, San Francisco, CA, USA. Balce DR; Vir Biotechnology, San Francisco, CA, USA. Bartha I; Vir Biotechnology, San Francisco, CA, USA. Meury M; Vir Biotechnology, San Francisco, CA, USA. Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK. Belnap DM; School of Biological Sciences, Department of Biochemistry, University of Utah, Salt Lake City, UT, USA. Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Schaiff WT; Vir Biotechnology, St. Louis, MO, USA. Miller JL; Vir Biotechnology, San Francisco, CA, USA. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Purcell LA; Vir Biotechnology, San Francisco, CA, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA, USA. . Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Jul; Vol. 619 (7970), pp. E50.
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Autorzy:
Momont C; Vir Biotechnology, San Francisco, CA, USA. Dang HV; Vir Biotechnology, San Francisco, CA, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Hauser K; Vir Biotechnology, San Francisco, CA, USA. Wang C; Vir Biotechnology, St. Louis, MO, USA. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Minola A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Branch K; Vir Biotechnology, San Francisco, CA, USA. Donermeyer D; Vir Biotechnology, St. Louis, MO, USA. Vyas S; Vir Biotechnology, San Francisco, CA, USA. Chen A; Vir Biotechnology, San Francisco, CA, USA. Ferri E; Vir Biotechnology, San Francisco, CA, USA. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Powell AE; Vir Biotechnology, San Francisco, CA, USA. Spreafico R; Vir Biotechnology, San Francisco, CA, USA. Yim SS; Vir Biotechnology, San Francisco, CA, USA. Balce DR; Vir Biotechnology, San Francisco, CA, USA. Bartha I; Vir Biotechnology, San Francisco, CA, USA. Meury M; Vir Biotechnology, San Francisco, CA, USA. Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK. Belnap DM; School of Biological Sciences, Department of Biochemistry, University of Utah, Salt Lake City, UT, USA. Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Schaiff WT; Vir Biotechnology, St. Louis, MO, USA. Miller JL; Vir Biotechnology, San Francisco, CA, USA. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Purcell LA; Vir Biotechnology, San Francisco, CA, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA, USA. . Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Jun; Vol. 618 (7965), pp. 590-597. Date of Electronic Publication: 2023 May 31.
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA. Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA. Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. Dang HV; Vir Biotechnology, San Francisco, CA, USA. Hauser K; Vir Biotechnology, San Francisco, CA, USA. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Rivera W; Vir Biotechnology, San Francisco, CA, USA. Schnell G; Vir Biotechnology, San Francisco, CA, USA. Rajesh A; Vir Biotechnology, San Francisco, CA, USA. Zhou J; Vir Biotechnology, San Francisco, CA, USA. Farhat N; Vir Biotechnology, San Francisco, CA, USA. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA. Noack J; Vir Biotechnology, San Francisco, CA, USA. Lempp FA; Vir Biotechnology, San Francisco, CA, USA. Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium. Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium. Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia. Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland. Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France. Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France. Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France. Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium. Soriaga L; Vir Biotechnology, San Francisco, CA, USA. Purcell LA; Vir Biotechnology, San Francisco, CA, USA. Snell G; Vir Biotechnology, San Francisco, CA, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. PizzutoMS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Autorzy:
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Datir RP; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA. Bowen J; Department of Biochemistry, University of Washington, Seattle, WA, USA. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA, USA. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy. Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK. Kingston N; NIHR Bioresource, Cambridge, UK. Graves B; NIHR Bioresource, Cambridge, UK. McCoy LE; Division of Infection and Immunity, University College London, London, UK. Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK. Temperton N; University of Kent, Canturbury, UK. Ceron-Gutierrez L; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK. Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico. Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK. Virgin HW; Vir Biotechnology, San Francisco, CA, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK. Wills M; Department of Medicine, University of Cambridge, Cambridge, UK. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. .; Department of Medicine, University of Cambridge, Cambridge, UK. .; Department of Haematology, University of Cambridge, Cambridge, UK. .; University of KwaZulu Natal, Durban, South Africa. .; Africa Health Research Institute, Durban, South Africa. .; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. .
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Autorzy:
Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Abdullahi A; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Goonawardane N; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan. Kimura I; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Yamasoba D; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Gerber PP; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Fatihi S; CSIR Institute of Genomics and Integrative Biology, Delhi, India. Rathore S; CSIR Institute of Genomics and Integrative Biology, Delhi, India. Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA. Papa G; MRC-Laboratory of Molecular Biology, Cambridge, UK. Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Toyoda M; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Tan TS; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Kuramochi J; Kuramochi Clinic Interpark, Utsunomiya, Japan. Mitsunaga S; Human Genetics Laboratory, National Institute of Genetics, Mishima, Japan. Ueno T; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Brevini T; Department of Medicine, University of Cambridge, Cambridge, UK. Mallery DL; MRC-Laboratory of Molecular Biology, Cambridge, UK. Charles OJ; Division of Infection and Immunity, UCL, London, UK. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Joshi A; Department of Biochemistry, University of Washington, Seattle, WA, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Department of Virology, University of Cambridge, Cambridge, UK. Jackson L; Africa Health Research Institute, Durban, South Africa. Martin D; University of Cape Town, Cape Town, South Africa. Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Bradley J; Department of Medicine, University of Cambridge, Cambridge, UK. Briggs JAG; Max Planck Institute of Biochemistry, Martinsried, Germany. Choi J; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK. Madissoon E; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.; European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, UK. Meyer KB; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. Mlcochova P; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Ceron-Gutierrez L; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK. Doffinger R; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK. Teichmann SA; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.; Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK. Fisher AJ; Transplant and Regenerative Medicine Laboratory, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. de Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Hosmillo M; Department of Virology, University of Cambridge, Cambridge, UK. Lee JH; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK. James LC; MRC-Laboratory of Molecular Biology, Cambridge, UK. Thukral L; CSIR Institute of Genomics and Integrative Biology, Delhi, India. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA. Sigal A; Africa Health Research Institute, Durban, South Africa.; Max Planck Institute for Infection Biology, Berlin, Germany.; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Sampaziotis F; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK. Goodfellow IG; Department of Virology, University of Cambridge, Cambridge, UK. Matheson NJ; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.; NHS Blood and Transplant, Cambridge, UK. Sato K; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. .; CREST, Japan Science and Technology Agency, Saitama, Japan. . Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK. .; Department of Medicine, University of Cambridge, Cambridge, UK. .; Africa Health Research Institute, Durban, South Africa. .
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. VanBlargan LA; Department of Medicine, Washington University of School of Medicine, St Louis, MO, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Noack J; Vir Biotechnology, San Francisco, CA, USA. Farhat N; Vir Biotechnology, San Francisco, CA, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA. Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA. Dillen JR; Vir Biotechnology, San Francisco, CA, USA. Powell AE; Vir Biotechnology, San Francisco, CA, USA. Chen A; Vir Biotechnology, San Francisco, CA, USA. Maher C; Vir Biotechnology, San Francisco, CA, USA. Yin L; Vir Biotechnology, San Francisco, CA, USA. Sun D; Vir Biotechnology, San Francisco, CA, USA. Soriaga L; Vir Biotechnology, San Francisco, CA, USA. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Gustafsson C; ATUM, Newark, CA, USA. Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. Logue J; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. Iqbal NT; Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan. Mazzitelli I; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Geffner J; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Grifantini R; National Institute of Molecular Genetics, Milan, Italy. Chu H; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. Gori A; Infectious Disease Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. Riva A; Department of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC), Università di Milano, Milan, Italy. Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland. Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia. Cippà PE; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland. Franzetti-Pellanda A; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. Halfmann PJ; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. Kawaoka Y; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. Hebner C; Vir Biotechnology, San Francisco, CA, USA. Purcell LA; Vir Biotechnology, San Francisco, CA, USA. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA. Diamond MS; Department of Medicine, Washington University of School of Medicine, St Louis, MO, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.; National Institute of Molecular Genetics, Milan, Italy. Snell G; Vir Biotechnology, San Francisco, CA, USA. . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. .; Howard Hughes Medical Institute, Seattle, WA, USA. . Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2022 Feb; Vol. 602 (7898), pp. 664-670. Date of Electronic Publication: 2021 Dec 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Joshi A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Giurdanella M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Noack J; Vir Biotechnology, San Francisco, CA 94158, USA. Abdelnabi R; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium. Foo SC; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Neyts J; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Bloom JD; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Jan 28; Vol. 375 (6579), pp. 449-454. Date of Electronic Publication: 2022 Jan 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.
Autorzy:
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. Dang HV; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Franko N; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. Tilles SW; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. Logue J; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. Miranda MC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA. Ahlrichs M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA. Carter L; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. Van Voorhis WC; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Dec 24; Vol. 374 (6575), pp. 1621-1626. Date of Electronic Publication: 2021 Nov 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Autorzy:
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sauer MM; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA. Low JS; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Housley MP; Vir Biotechnology, San Francisco, CA 94158, USA. Noack J; Vir Biotechnology, San Francisco, CA 94158, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA. Jerak J; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA. Islam S; Vir Biotechnology, San Francisco, CA 94158, USA. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Foo C; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Coelmont L; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cassotta A; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Ceschi A; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland. Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia. Cippà PE; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Faculty of Medicine, University of Zurich, 8057 Zurich, Switzerland. Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland. Ceruti S; Intensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Riva A; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Smithey M; Vir Biotechnology, San Francisco, CA 94158, USA. Hong D; Vir Biotechnology, San Francisco, CA 94158, USA. Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA. Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; UT Southwestern Medical Center, Dallas, TX 75390, USA.; Washington University School of Medicine, St. Louis, MO 63110, USA. Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Sep 03; Vol. 373 (6559), pp. 1109-1116. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Autorzy:
Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA. Addetia A; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Hernandez P; Vir Biotechnology, San Francisco, CA, USA. Greaney AJ; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Genome Sciences, University of Washington, Seattle, WA, USA. Marzi R; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Glass WG; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Zhang I; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. Dingens AS; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA, USA. De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Zhou J; Vir Biotechnology, San Francisco, CA, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Dillen JR; Vir Biotechnology, San Francisco, CA, USA. Tucker H; Vir Biotechnology, San Francisco, CA, USA. Bassi J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Housley MP; Vir Biotechnology, San Francisco, CA, USA. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Lombardo G; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Agostini M; Vir Biotechnology, San Francisco, CA, USA. Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Meury M; Vir Biotechnology, San Francisco, CA, USA. Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Stumpf S; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK. Nix JC; Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA. Piccoli L; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Lempp FA; Vir Biotechnology, San Francisco, CA, USA. PizzutoMS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Chodera JD; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hebner CM; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Bloom JD; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Genome Sciences, University of Washington, Seattle, WA, USA. .; Howard Hughes Medical Institute, Seattle, WA, USA. . Snell G; Vir Biotechnology, San Francisco, CA, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 97-102. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Broad sarbecovirus neutralization by a human monoclonal antibody.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Wang Z; Department of Biochemistry, University of Washington, Seattle, WA, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Housley MP; Vir Biotechnology, San Francisco, CA, USA. Lempp FA; Vir Biotechnology, San Francisco, CA, USA. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA. Zhou J; Vir Biotechnology, San Francisco, CA, USA. Addetia A; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Guarino B; Vir Biotechnology, San Francisco, CA, USA. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Giacchetto-Sasselli I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA. Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Snell G; Vir Biotechnology, San Francisco, CA, USA. Bloom JD; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. . PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 103-108. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Autorzy:
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Chen A; Vir Biotechnology, San Francisco, CA 94158, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Navarro MJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Agostini M; Vir Biotechnology, San Francisco, CA 94158, USA. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Tilles SW; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Guastalla SB; Independent physician, 6828 Balerna, Switzerland. Bona G; Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Pellanda AF; Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Van Voorhis WC; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. . Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. .
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Aug 06; Vol. 373 (6555), pp. 648-654. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Recombinant Human Secretory IgA Induces Salmonella Typhimurium Agglutination and Limits Bacterial Invasion into Gut-Associated Lymphoid Tissues.
Autorzy:
Richards AF; Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York 12208, United States.; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States. Baranova DE; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States. PizzutoMS; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., 6500 Bellinzona, Switzerland. Jaconi S; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., 6500 Bellinzona, Switzerland. Willsey GG; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States. Torres-Velez FJ; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States. Doering JE; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States. Benigni F; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., 6500 Bellinzona, Switzerland. Corti D; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., 6500 Bellinzona, Switzerland. Mantis NJ; Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York 12208, United States.; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States.
Pokaż więcej
Źródło:
ACS infectious diseases [ACS Infect Dis] 2021 May 14; Vol. 7 (5), pp. 1221-1235. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Autorzy:
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Datir RP; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA. Bowen J; Department of Biochemistry, University of Washington, Seattle, WA, USA. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA, USA. PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy. Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK. Kingston N; NIHR Bioresource, Cambridge, UK. Graves B; NIHR Bioresource, Cambridge, UK. McCoy LE; Division of Infection and Immunity, University College London, London, UK. Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK. Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK. Temperton N; University of Kent, Canturbury, UK. Ceron-Gutierrez L; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK. Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico. Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK. Virgin HW; Vir Biotechnology, San Francisco, CA, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK. Wills M; Department of Medicine, University of Cambridge, Cambridge, UK. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. .; Department of Medicine, University of Cambridge, Cambridge, UK. .; Department of Haematology, University of Cambridge, Cambridge, UK. .; University of KwaZulu Natal, Durban, South Africa. .; Africa Health Research Institute, Durban, South Africa. .; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. .
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Autorzy:
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Chen A; Vir Biotechnology, San Francisco, CA 94158, USA. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Zepeda S; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA. Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium. Rothlauf PW; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Bloyet LM; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium. Riva A; III Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, 20157 Milan, Italy. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: . PizzutoMS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell [Cell] 2021 Apr 29; Vol. 184 (9), pp. 2332-2347.e16. Date of Electronic Publication: 2021 Mar 16.
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France. Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA. Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Dang HV; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Minola A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Guarino B; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bianchi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Lauron EJ; Vir Biotechnology, San Francisco, CA 94158, USA. Tucker H; Vir Biotechnology, San Francisco, CA 94158, USA. Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA. Peter A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA. Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA 94158, USA. Case JB; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Chen RE; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA. Meury M; Vir Biotechnology, San Francisco, CA 94158, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA. Spreafico R; Vir Biotechnology, San Francisco, CA 94158, USA. Dillen J; Vir Biotechnology, San Francisco, CA 94158, USA. Ng C; Vir Biotechnology, San Francisco, CA 94158, USA. Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium. Schmid MA; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Riva A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy. Gabrieli A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy. Galli M; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy. PizzutoMS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium. Diamond MS; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Washington University School of Medicine, St. Louis, MO, USA.; UTSouthwestern Medical Center, Dallas, TX, USA. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Fink K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. .
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2020 Nov 20; Vol. 370 (6519), pp. 950-957. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Autorzy:
Piccoli L; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Park YJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, 75015 Paris, France. Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Beltramello M; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Silacci-Fregni C; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Pinto D; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Acton OJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Jaconi S; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Guarino B; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Minola A; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Zatta F; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Sprugasci N; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Bassi J; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Peter A; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. De Marco A; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Nix JC; Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. Mele F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Jovic S; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Rodriguez BF; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Gupta SV; Vir Biotechnology, San Francisco, CA 94158, USA. Jin F; Vir Biotechnology, San Francisco, CA 94158, USA. Piumatti G; Division of Primary Care, Geneva University Hospitals, 1205 Geneva, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland. Lo Presti G; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Biggiogero M; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Tarkowski M; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy. PizzutoMS; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Cameroni E; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA. Smithey M; Vir Biotechnology, San Francisco, CA 94158, USA. Hong D; Vir Biotechnology, San Francisco, CA 94158, USA. Lepori V; Independent Physician, 6500 Bellinzona, Switzerland. Albanese E; Institute of Public Health, Università della Svizzera italiana, 6900 Lugano, Switzerland. Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland. Bernasconi E; Division of Infectious Diseases, Ente Ospedaliero Cantonale, Ospedale Civico and Ospedale Italiano, 6900 Lugano, Switzerland. Elzi L; Division of Infectious Diseases, Ente Ospedaliero Cantonale, Ospedale Regionale Bellinzona e Valli and Ospedale Regionale, 6600 Locarno, Switzerland. Ferrari P; Department of Nephrology, Ospedale Civico Lugano, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, NSW 2052, Australia. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Riva A; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Fink K; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA. Lanzavecchia A; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Corti D; Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell [Cell] 2020 Nov 12; Vol. 183 (4), pp. 1024-1042.e21. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection.
Autorzy:
Perruzza L; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), Bellinzona, Switzerland. Jaconi S; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland. Lombardo G; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland. Pinna D; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland. Strati F; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), Bellinzona, Switzerland. Morone D; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), Bellinzona, Switzerland. Seehusen F; Laboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. Hu Y; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Bajoria S; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Xiong J; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Kumru OS; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Joshi SB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Volkin DB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, United States. Piantanida R; Department of Otolaryngology-Head and Neck Surgery, Ospedale Regionale di Lugano, Lugano, Switzerland. Benigni F; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland. Grassi F; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), Bellinzona, Switzerland. Corti D; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland. PizzutoMS; Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc., Bellinzona, Switzerland.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2020 Jun 09; Vol. 11, pp. 1011. Date of Electronic Publication: 2020 Jun 09 (Print Publication: 2020).
Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
Autorzy:
Coppe A; Department of Molecular Medicine, University of Padova, Padova, Italy. Nogara L; Department of Biomedical Sciences, University of Padova, Padova, Italy. PizzutoMS; Laboratory of Onco-Hematology, Department of Women's and Children's Health, University of Padova, Padova, Italy. Cani A; Laboratory of Onco-Hematology, Department of Women's and Children's Health, University of Padova, Padova, Italy. Cesaro S; Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Masetti R; Oncologia ed Ematologia Pediatrica 'Lalla Seràgnoli', University of Bologna, Bologna, Italy. Locatelli F; Department of Pediatric Onco-Hematology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy. Te Kronnie G; Laboratory of Onco-Hematology, Department of Women's and Children's Health, University of Padova, Padova, Italy. Basso G; Laboratory of Onco-Hematology, Department of Women's and Children's Health, University of Padova, Padova, Italy. Bortoluzzi S; Department of Molecular Medicine, University of Padova, Padova, Italy. Bresolin S; Laboratory of Onco-Hematology, Department of Women's and Children's Health, University of Padova, Padova, Italy.
Pokaż więcej
Źródło:
Human mutation [Hum Mutat] 2018 Apr; Vol. 39 (4), pp. 579-587. Date of Electronic Publication: 2018 Jan 19.
Improving heat stability of haemagglutinating antigens for avian influenza.
Autorzy:
PizzutoMS; OIE/FAO and National Reference Laboratory for Newcastle Disease and Avian Influenza, OIE Collaborating Centre for Epidemiology, Training and Control of Emerging Avian Diseases, Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università, Legnaro, Padova, Italy. />De Benedictis P Maniero S Toson M Dundon WG M'Baye Seck B Capua I
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies